UCT RC&I Congratulates Strait Access Technologies on First-in-Human Clinical Trial

The University of Cape Town’s Research Contracts & Innovation (RC&I) congratulates Strait Access Technologies (SAT) on the initiation of its first-in-human clinical trial, marking an important milestone in the translation of research into clinical practice.

SAT, a medical technology company developing next-generation cardiovascular devices, has successfully completed the first-in-human use of its CenterFlow® post-TEVAR stent-graft balloon moulding catheter. This achievement reflects years of focused development and progression from early-stage research through product development and into clinical evaluation.

Dr Andrew Bailey, Director of UCT RC&I, says, “Initiating a first-in-human trial is one of the most significant steps in the innovation journey. It signals that a technology has matured to a point where it can begin demonstrating real-world clinical value. We commend the Strait Access Technologies team for reaching this milestone and for their commitment to translating research into solutions with the potential to improve patient outcomes.”

The first-in-human experience confirms the clinical relevance of CenterFlow® and highlights its potential to advance post-TEVAR stent-graft moulding. By extending the effective treatment window from seconds to minutes while maintaining stability and radial force, the CenterFlow®  represents a meaningful development in aortic endovascular therapy.

UCT RC&I is proud to support innovations progressing from the laboratory into clinical settings and looks forward to the outcomes of this trial and Strait Access Technologies’ continued advancement.

Read more about the first-in-human-trial here